Clinical Trial

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-11; most recent amendment 2026-06-18.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Status change: Not Yet Recruiting → Recruiting 2023-08-08
Trial Details
NCT Number NCT05825625
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Conditions Non-small Cell Lung Cancer
Enrollment 35 participants
Start Date 2023-05-26
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23